IOVANCE BIOTHERAPEUTICS
Iovance Biotherapeutics is focused on the development and commercialization of novel cancer immunotherapies based on tumor infiltrating lymphocytes (TIL). Under a collaborative research and development agreement with Dr. Steven A. Rosenberg at the National Cancer Institute, we are investigating our our lead product candidate, LN-144, in the treatment of stage 4 metastatic melanoma. In clinical trials, LN-144 has demonstrated curative potential in patients with metastatic melanoma, and it may also be applicable to a wide range of other solid tumors.
IOVANCE BIOTHERAPEUTICS
Industry:
Biotechnology Health Care Medical
Founded:
2007-01-01
Address:
New York, New York, United States
Country:
United States
Website Url:
http://www.iovance.com
Total Employee:
251+
Status:
Active
Contact:
(212)946-4856
Total Funding:
1.22 B USD
Technology used in webpage:
IPv6 GoDaddy DNS COVID-19 Akamai Hosted Rackspace
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
CEL-SCI
CEL-SCI is a biotechnology company developing immunotherapy products for the treatment of cancer and other infectious diseases.
Elicio Therapeutics
Elicio Therapeutics develops an immuno-tumor vaccine to treat cancer.
Gracell Biotechnologies
Gracell Biotechnologies is a developer of cancer immune therapy designed to treat cancer.
Harpoon Therapeutics
Harpoon Therapeutics is a clinical-stage immunotherapy company developing novel T cell engagers (TriTACs) for the treatment of cancer.
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2013-10-31 | Genesis Biopharma | Genesis Biopharma acquired by Iovance Biotherapeutics | N/A |
Investors List
OrbiMed
OrbiMed investment in Post-IPO Equity - Iovance Biotherapeutics
Broadfin Capital
Broadfin Capital investment in Post-IPO Equity - Iovance Biotherapeutics
Quogue Capital
Quogue Capital investment in Post-IPO Equity - Iovance Biotherapeutics
Frazier Healthcare Partners
Frazier Healthcare Partners investment in Post-IPO Equity - Iovance Biotherapeutics
Official Site Inspections
http://www.iovance.com Semrush global rank: 616.87 K Semrush visits lastest month: 72.59 K
- Host name: server-3-162-125-67.iad61.r.cloudfront.net
- IP address: 3.162.125.67
- Location: Seattle United States
- Latitude: 47.6348
- Longitude: -122.3451
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98109
More informations about "Iovance Biotherapeutics"
About Us - Iovance Biotherapeutics
About Iovance Biotherapeutics. Iovance Biotherapeutics aims to be the global leader in innovating, developing and delivering tumor infiltrating lymphocyte (TIL) therapy for people …See details»
Our Culture - Iovance Biotherapeutics
We are a patient-centric, collaborative organization that is driven to change the way cancer is treated. We are agile in our thinking and strive for excellence and innovation while acting with …See details»
IovanceCares
Patient Advocacy Organization Referrals Patients and their families may face financial, emotional, and logistical challenges when they are referred for Iovance products. Iovance provides a …See details»
Iovance Biotherapeutics, Inc. | LinkedIn
Iovance Biotherapeutics, Inc. Biotechnology Research San Carlos, California 25,571 followers Iovance is a patient-centric, collaborative organization that is driven to change the way cancer …See details»
Iovance Biotherapeutics - Crunchbase Company Profile …
Iovance Biotherapeutics is focused on the development and commercialization of novel cancer immunotherapies based on tumor infiltrating lymphocytes (TIL). The company is preparing for potential regulatory approval and marketing of the …See details»
Iovance Biotherapeutics, Inc.: Culture - LinkedIn
Iovance Biotherapeutics, Inc. Biotechnology Research San Carlos, California 25,243 followers Iovance is a patient-centric, collaborative organization that is driven to change the way cancer …See details»
Iovance Biotherapeutics - Wikipedia
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer. [ 1 ] [ 2 ]See details»
Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2021 ...
A strong organization of approximately 350 employees with an average of more than four years of cell therapy experience is in place to advance research, development, manufacturing, and …See details»
CHARTER OF THE NOMINATING AND CORPORATE GOVERNANCE …
Organization and Governance of the Nominating and Corporate Governance Committee The Nominating and Corporate Governance Committee (the “Committee”) of Iovance …See details»
Corporate Overview - Iovance Biotherapeutics
Certain matters discussed in this press release are “forward-looking statements” of Iovance Biotherapeutics, Inc. (hereinafter referred to as the “Company,” “we,” “us,” or “our”) within the …See details»
Management Biographies – Iovance Biotherapeutics
Prior to joining Iovance, Dr. Vogt practiced law at the international firm of Morgan, Lewis & Bockius, focusing on intellectual property and business law in the life sciences and …See details»
Iovance Biotherapeutics Company Description - Stock Analysis
1 day ago Iovance Biotherapeutics Company Description Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using …See details»
Why Iovance Biotherapeutics Inc. (IOVA) Is Skyrocketing - Yahoo …
Jan 2, 2025 Iovance Biotherapeutics (IOVA) is a biopharmaceutical company that aims to be a global leader in innovating, developing, and delivering tumor-infiltrating lymphocyte therapy for …See details»
Iovance Q3 Revenue Surges to $58.6M as Amtagvi Launch Gains …
Nov 7, 2024 1. World Health Organization International Agency for Research on Cancer (IARC) GLOBOCAN 2022. About Iovance Biotherapeutics, Inc. Iovance Biotherapeutics, Inc. aims to …See details»
Iovance Biotherapeutics Reports Financial Results and Corporate …
Nov 7, 2024 Iovance Biotherapeutics, Inc. Significant Demand for Amtagvi™ (Lifileucel) Continues with $58.6M in Total 3Q24 Product Revenue. Reaffirming Guidance of $160-$165M …See details»
Iovance Biotherapeutics Reports Second Quarter and First Half …
Executive leadership team and talented organization with deep cell therapy experience. Second Quarter 2022 Highlights and Recent Corporate Updates Regulatory Iovance TIL therapy …See details»
Board of Directors – Iovance Biotherapeutics
In that role, Ms. Yarno led an organization charged with global commercialization strategy and all aspects of supporting pre-and post-launch commercialization of pharmaceuticals in more than …See details»
Iovance Biotherapeutics Reports Financial Results and Corporate …
Aug 8, 2024 Iovance Biotherapeutics, Inc. Strong Momentum Continues for Amtagvi™ (Lifileucel) U.S. Launch with $31.1 Million in Total 2Q24 Revenue. Total Product Revenue …See details»
Iovance Biotherapeutics, Inc. (LON: 0JDK) - Stock Analysis
Dec 30, 2024 Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for …See details»
Iovance Biotherapeutics Reports Financial Results and Corporate …
Nov 7, 2024 Iovance is also activating sites in additional regions with strong track records for enrollment in NSCLC studies. Iovance expects to present updated data from the IOV-LUN-202 …See details»